← Leaderboards
Florian R Schroeck
Veterans Education/Res/Assn/North/Ne
$1,482,715
Attributed
$1,482,715
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $583.9K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,482,715 · 1
VA$0 · 1
By mechanism
R37$1,482,715 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Monitor”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Kimberly Smith · Ppd Development Lp$116,656,661
- Yunda Huang · Fred Hutchinson Cancer Center$71,488,059
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Martha Hering · Westat, Inc.$57,098,843
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
MonitorAffectRecurrenceAnxietyBladderMalignant Neoplasm Of Urinary BladderMalignant NeoplasmsProceduresCystoscopySiteAlgorithmsCancer TypeCare SystemsCaringAreaDisorder RiskEffectivenessData SetCodeCluster Randomized TrialAdoptionDiagnosisConsensusClinical Trials
Grant awards (8)
Replacing Invasive Cystoscopy with Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance$332,897
R37 · FY2025 · CA · contact PI
Replacing Invasive Cystoscopy with Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance$565,926
R37 · FY2024 · CA · contact PI
Replacing Invasive Cystoscopy with Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance$583,892
R37 · FY2023 · CA · contact PI
Implementing Risk-aligned Bladder Cancer Surveillance$0
I01 · FY2023 · VA · contact PI
Implementing Risk-aligned Bladder Cancer Surveillance$0
I01 · FY2022 · VA · contact PI
Implementing Risk-aligned Bladder Cancer Surveillance$0
I01 · FY2021 · VA · contact PI
Implementing Risk-aligned Bladder Cancer Surveillance$0
I01 · FY2021 · VA · contact PI
Implementing Risk-aligned Bladder Cancer Surveillance$0
I01 · FY2020 · VA · contact PI